SGEN - Earnings announcements

Expects to close Seagen acquisition on December 14, 2023 Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution Pfizer to host analyst and investor call at 8:30 am EST on Wednesday, December 13, 2023, to discuss the Seagen acquisition, new commercial organization, and provide full-year 2024 financial guidance Pfizer Inc. (NYSE:PFE) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer's pending acquisition of Seagen Inc. (NASDAQ:SGEN). Pfizer and Seagen have now received all required regulatory approvals to complete

-Record Net Product Sales of $571 Million in 3Q23, a 33% Increase Over 3Q22, Primarily Driven by PADCEV® First-Line Launch- -PADCEV with Keytruda® Potentially Practice Changing for First-Line Metastatic Urothelial Cancer after EV-302 Trial Demonstrates Near Doubling of Median Overall Survival- -Proposed Pfizer Transaction On-Track and Anticipated to Close in Late-2023 or Early-2024, Subject to Closing Conditions, with Ongoing FTC Review and Recent EC Approval- Seagen Inc. (NASDAQ:SGEN) (Seagen or the Company) reported financial results today for the third quarter ended September 30, 2023. David Epstein, Chief Executive Officer of Seagen said, "Seagen continues to build momentum in 2

Seagen Inc. (NASDAQ:SGEN) announced today that it will report third quarter 2023 financial results on Wednesday, November 1, 2023. Given the previously announced agreement to be acquired by Pfizer Inc., Seagen will not be hosting a conference call. About Seagen Founded 25 years ago, Seagen Inc. is a global biotechnology company that discovers, develops, manufactures and commercializes targeted cancer therapeutics, with antibody-drug conjugates (ADCs) at our core. Our colleagues work together with urgency to improve and extend the lives of people living with cancer. An ADC technology trailblazer, approximately one-third of FDA-approved and marketed ADCs use Seagen technology. Seagen is

-Record Net Product Sales of $544 Million in 2Q23, an Increase of 26% Over 2Q22, Contributing to Total Revenues of $604 Million in 2Q23- -Strong PADCEV® Growth Driven By Combination First-Line Advanced Urothelial Cancer Launch; Record ADCETRIS® Performance with Overall Survival Benefit Demonstrated in the ECHELON-1 Trial Added to Label- -Three Registrational Trial Readouts for PADCEV, TUKYSA® and TIVDAK® Anticipated in 2H23- -Initiated Phase 3 Trial for Disitamab Vedotin and Expect to Initiate Phase 3 Trial of SGN-B6A by Year End- -Proposed Acquisition by Pfizer Progressing Towards Close in Late 2023 or Early 2024- Seagen Inc. (NASDAQ:SGEN) (Seagen or the Company) reported financi

Seagen Inc. (NASDAQ:SGEN) today announced that it will report its second quarter 2023 financial results on Wednesday, August 2, 2023. Given the previously announced agreement to be acquired by Pfizer Inc., Seagen will not be hosting a conference call. About Seagen Founded 25 years ago, Seagen Inc. is a global biotechnology company that discovers, develops, manufactures and commercializes targeted cancer therapeutics, with antibody-drug conjugates (ADCs) at our core. Our colleagues work together with urgency to improve and extend the lives of people living with cancer. An ADC technology trailblazer, approximately one-third of FDA-approved and marketed ADCs use Seagen technology. Seagen

-Total Revenues of $520 Million in 1Q23, Including Net Product Sales of $469 Million- -PADCEV® Granted FDA Accelerated Approval in Combination with KEYTRUDA® as First-Line Treatment for Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer- -Presented Data at AACR on Multiple Targeted Cancer Pipeline Assets Highlighting Emerging Next-Generation Antibody Drug Conjugate (ADC) Technologies- -Previously Announced Agreement to be Acquired by Pfizer with Transaction Expected to Close Late 2023 or Early 2024- Seagen Inc. (NASDAQ:SGEN) (Seagen or the Company) reported financial results today for the first quarter ended March 31, 2023. The Company also highlight

Seagen Inc. (NASDAQ:SGEN) today announced that it will report its first quarter 2023 financial results on Thursday, April 27, 2023. Given the recently announced agreement to be acquired by Pfizer Inc., Seagen will not be hosting a conference call. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twit

Pfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion Proposed combination enhances Pfizer's position as a leading company in Oncology Seagen's medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates (ADCs) strongly complement Pfizer's Oncology portfolio Seagen expected to contribute more than $10 billion in risk-adjusted revenues in 2030 Pfizer and Seagen to hold analyst and investor call at 8 a.m. EDT today Pfizer Inc. (NYSE:PFE) and Seagen Inc. (NASDAQ:SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a gl

-Total Revenues of $2.0 Billion in 2022, Including 23 Percent Annual Increase in Total Net Product Sales to $1.7 Billion- -TUKYSA Granted FDA Accelerated Approval for Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer- -ADCETRIS Received Pediatric Indication with FDA Approval for Children with Previously Untreated High Risk Hodgkin Lymphoma- -Multiple Key Milestones Anticipated in 2023, including Potential Label Expansion, Key Data Readouts and Additional International Launches for Current Products- -Conference Call Today at 4:30 p.m. ET- Seagen Inc. (NASDAQ:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2022. The Com

Seagen Inc. (NASDAQ:SGEN) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Conference call and webcast information: Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international). Ask for the Seagen conference call. Webcast with slides can be accessed at investor.seagen.com. A webcast replay will be archived on the Company's website. About Seagen Seagen is a global biotechnology company that discovers

-Total Revenues of $510 Million in 3Q22, Including Net Product Sales of $428 Million- -Submitted Supplemental Biologics License Application to FDA for PADCEV in Combination with KEYTRUDA as First-Line Treatment for Advanced Urothelial Cancer- -Announced FDA Granted Priority Review for TUKYSA in Combination with Trastuzumab for Previously Treated HER2-Positive Metastatic Colorectal Cancer- -Conference Call Today at 4:30 p.m. ET- Seagen Inc. (NASDAQ:SGEN) reported financial results today for the third quarter ended September 30, 2022. The Company also highlighted PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), ADCETRIS® (brentuximab vedotin) and TIVDAK® (tisotumab vedotin-tftv) co

Seagen Inc. (NASDAQ:SGEN) today announced that it will report its third quarter 2022 financial results on Thursday, October 27, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Conference call and webcast information: Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 10171976 Webcast with slides can be accessed at investor.seagen.com. A webcast replay will be archived on the Company's website. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes

-Total Revenues of $498 Million in 2Q22, Including Net Product Sales of $432 Million- -Announced Positive Topline Results for PADCEV with KEYTRUDA as First-Line Treatment for Advanced Urothelial Cancer- -Presented Positive Results from Pivotal MOUNTAINEER Trial Demonstrating Antitumor Activity of TUKYSA in Combination with Trastuzumab for Previously Treated HER2-Positive Metastatic Colorectal Cancer- -Conference Call Today at 4:30 p.m. ET- Seagen Inc. (NASDAQ:SGEN) reported financial results today for the second quarter ended June 30, 2022. The Company also highlighted PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), ADCETRIS® (brentuximab vedotin) and TIVDAK® (tisotumab vedotin-

Seagen Inc. (NASDAQ:SGEN) today announced that it will report its second quarter 2022 financial results on Thursday, July 28, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Conference call and webcast information: Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 10167970 Webcast with slides can be accessed at investor.seagen.com. A webcast replay will be archived on the Company's website. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes tr

-Total Revenues of $426 Million in 1Q22, Including Net Product Sales of $383 Million- -PADCEV® Approved by European Commission for Previously Treated Locally Advanced or Metastatic Urothelial Cancer- -ADCETRIS® Overall Survival Data in Newly Diagnosed Advanced Hodgkin Lymphoma Patients to be Presented in Oral Session at ASCO Annual Meeting- -Conference Call Today at 4:30 p.m. ET- Seagen Inc. (NASDAQ:SGEN) reported financial results today for the first quarter ended March 31, 2022. The Company also highlighted PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), ADCETRIS® (brentuximab vedotin) and TIVDAK® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as

Seagen Inc. (NASDAQ:SGEN) today announced that it will report its first quarter 2022 financial results on Thursday, April 28, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Conference call and webcast information: Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 10165175 Webcast with slides can be accessed at investor.seagen.com. A webcast replay will be archived on the Company's website. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes tr

-Total Revenues of $1.6 Billion in 2021, Including 38 Percent Annual Increase in Total Net Product Sales to $1.4 Billion- -Growth Across Commercial Portfolio of Four Oncology Products- -ADCETRIS® (brentuximab vedotin) Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma- -Multiple Key Milestones Anticipated in 2022- -Conference Call Today at 4:30 p.m. ET- Seagen Inc. (NASDAQ:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2021. The Company also highlighted ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib) and TIVDAK® (tisotumab vedotin-tftv) commerci

Seagen Inc. (NASDAQ:SGEN) today announced that it will report its fourth quarter and full year 2021 financial results on Wednesday, February 9, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Conference call and webcast information: Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 10163004 Webcast with slides can be accessed at investor.seagen.com. A webcast replay will be archived on the Company's website. About Seagen Seagen is a global biotechnology company that discovers, develops and

-Total Net Product Sales of $366.5 Million in 3Q21, an Increase of 37 Percent Over 3Q20- -FDA Granted TIVDAK Accelerated Approval for Previously Treated Recurrent or Metastatic Cervical Cancer- -Completed Enrollment in both PADCEV EV-103 Trial Cohort K in First-Line Metastatic Urothelial Cancer and in TUKYSA MOUNTAINEER Trial in Previously Treated HER2-Positive Metastatic Colorectal Cancer- -Entered into Exclusive Worldwide License and Co-Development Agreement with RemeGen for Disitamab Vedotin, a Novel HER2-targeted Antibody-Drug Conjugate- -Conference Call Today at 4:30 p.m. ET- Seagen Inc. (NASDAQ:SGEN) reported financial results today for the third quarter and nine months ended Sep

Seagen Inc. (NASDAQ:SGEN) today announced that it will report its third quarter 2021 financial results on Thursday, October 28, 2021 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Access to the event can be obtained as follows: Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 10160629 Webcast with slides can be accessed at investor.seagen.com. A webcast replay will be archived on the Company's website. About Seagen Seagen is a global biotechnology company that discovers, develops and

Seagen Inc. (NASDAQ:SGEN) will host a conference call and webcast on Tuesday, September 21, 2021 to discuss the U.S. Food and Drug Administration approval of TIVDAK™ (tisotumab vedotin-tftv). Access to the event can be obtained as follows: September 21, 2021 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 10160278 Webcast with slides will be available at www.seagen.com in the Investors section. A webcast replay will be archived on the Company's website. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful d

-Record Quarterly Sales for Each of ADCETRIS, PADCEV and TUKYSA; Total Net Product Sales of $347.3 Million in 2Q21, an Increase of 44 Percent Over 2Q20- -FDA Grants PADCEV Regular Approval and Adds New Indication for Locally Advanced or Metastatic Urothelial Cancer- -Tisotumab Vedotin BLA Under FDA Priority Review with PDUFA Date of October 10, 2021- -Conference Call Today at 4:30 p.m. ET- Seagen Inc. (NASDAQ:SGEN) today reported financial results for the second quarter and six months ended June 30, 2021. The Company also highlighted ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv) and TUKYSA® (tucatinib) commercial and development accomplishments, as well as progres